IPP Bureau
Aurigene reports results of AUR101 in phase II study in US patients
By IPP Bureau - December 19, 2022
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Stake sale in GMM Pfaudler by Pfaudler
By IPP Bureau - December 19, 2022
Post the sale, Patel family has become the single largest promoter shareholder in the company
Sun Pharmaceutical receives warning letter from USFDA for Halol facility
By IPP Bureau - December 19, 2022
The Halol facility was placed under Import Alert by USFDA.
Mandaviya inaugurates ICMR-NARFBR in Hyderabad
By IPP Bureau - December 19, 2022
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Emmes appoints Ching Tian as Chief Innovation Officer
By IPP Bureau - December 16, 2022
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
NHA releases consultation paper on Operationalising Unified Health Interface
By IPP Bureau - December 16, 2022
UHI is envisioned as a foundational layer of the Ayushman Bharat Digital Mission and aims to enable interoperability in health services in India through open protocols
Synchron raises $75 mn Series C Led by ARCH Venture Partners
By IPP Bureau - December 16, 2022
Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X join ARCH as new additional investors
Mandaviya asserts govt's commitment towards improving access to quality medical education
By IPP Bureau - December 16, 2022
India now has 648 medical colleges in 2022 with a whopping 96% increase in the number of Government Medical Colleges (GMC) alone and a 42% increase in the private sector, since 2014
China aims to lead next bio revolution in advanced biologics, says GlobalData
By IPP Bureau - December 15, 2022
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
Takeda launches CINRYZE in India for hereditary angioedema patients
By IPP Bureau - December 15, 2022
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
ELIX Polymers and Ayudame3D to produce prostheses using recovered ABS
By IPP Bureau - December 15, 2022
Ayúdame3D has become a leading social entity in social technology.
Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
By IPP Bureau - December 15, 2022
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Torrent enters into co-marketing partnership with Boehringer Ingelheim India
By IPP Bureau - December 15, 2022
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
Briefs: Jubilant Pharmova and Apollo Hospitals Enterprise
By IPP Bureau - December 15, 2022
The company will submit an action plan on the observations and will engage with US FDA for next steps.
Kerala Ayurveda receives US patent for its herbal formulation
By IPP Bureau - December 15, 2022
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
